QualityDipStocks / Health Care · Pharmaceuticals
Vicore Pharma Holding AB VCRE
Outside our quality screen, so we don’t track its dips. It’s 41% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for VCRE: Operating cash flow not tagged in SEC XBRL data. We’d rather show nothing than a made-up number.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
GrowthSales grew 27% in the latest quarter vs a year ago.
Top bearish points 2 of 5
ProfitabilityOperating margin is only 0.0% over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; debt load unclear or high.
All fundamentals
from SEC filings
No fundamentals for Vicore Pharma Holding AB: Revenue and earnings aren't tagged in SEC XBRL data. We show nothing rather than guess.
The business
FCF $-0.3B · Sales +27%
- Free cash flow, 12 months−$0.3B
- Free-cash-flow yield−10.4%
- Gross margin100%
- Operating margin0%
- Return on equity−57%
- Sales growth (latest quarter vs year-ago quarter)+27%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $9.59
- 52-wk lowlowest close, 1 year$8.66−9.7%
- PriceMon Nov 2 close$9.59you are here
- 52-wk highhighest close, 1 year$16.25+69.4%
Momentum & 52-week range
5 days +2.0%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
VCRE is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Vicore Pharma Holding AB in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.